(Alliance News) - The FTSE 100 index was higher at midday in London on Wednesday, buoyed by market confidence that the US Federal Reserve will hold interest rates steady later in the day, as well as a major merger announcement from telecommunications firm Vodafone. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday. Read More
(Alliance News) - Aptamer Group PLC said on Wednesday that it has partnered with Neuro-Bio Ltd and declared success in the development of a lateral flow test to diagnose early Alzheimer's disease. Read More
Aptamer Group PLC - York, England-based company that develops custom affinity binders through its Optimer platform to enable new approaches in therapeutics, diagnostics and research applications - Chief Executive Officer Arron Tolley leaves his position and the board immediately. Tolley will remain with Aptamer for a period of garden leave. Chair Ian Gilham will become executive chair, and Chief Financial Officer Rob Quinn will take on the additional role of interim CEO. Aptamer will "immediately" begin search for a full-time CEO. Read More
(Alliance News) - Stocks in London were higher at the close on Friday, ahead of a long bank holiday weekend, as the latest US jobs report made a recession across the Atlantic appear less likely. Read More
(Alliance News) - Stock prices in London were higher at midday on Friday, a better end to a nervy week for equities, with investors digesting central bank decisions and an ongoing crisis in the US regional banking sector. Read More
(Alliance News) - Aptamer Group PLC said on Friday it expects "significantly lower" revenue for this financial year and blamed figures for the past ten months on slower-than-expected conversion of its pipeline. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday. Read More
(Alliance News) - Aptamer Group PLC on Monday expanded its Optimer binder pipeline with the launch of Optimer-Fc, a new reagent solution for immunohistochemistry. Read More
(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
Aptamer Group PLC - York, England-based company which develops custom affinity binders through its Optimer platform to enable new approaches in therapeutics, diagnostics and research applications - Appoints Rob Quinn as chief financial and as an executive director of the board, effective from March 1. Quinn was previously CFO at Pharnext, a biotech company in Paris. Read More
(Alliance News) - Aptamer Group PLC on Monday said it has signed a follow on deal to develop Optimer binders as novel solutions for a direct-to-consumer personal care product. Read More
(Alliance News) - Aptamer Group PLC on Tuesday celebrated a "solid start" to the second half, after signing two new contracts with the potential for downstream milestone and licencing payments. Read More
(Alliance News) - Aptamer Group PLC on Tuesday warned it will miss its full-year revenue target, as headwinds continued into the new financial year. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
Aptamer Group PLC - York, England-based provider of custom services, diagnostics and therapeutics for biotechnology and pharmaceutical firms - Opens its new 18,000 square feet facilities in York Science Park in the UK. Says the facilities will allow the company to meet the increasing demand for optimer technology. "This state-of-the-art site will help to expand the capacity of Aptamer's proprietary Optimer platform to deliver novel binders for scientists across the bioprocessing, diagnostic, and drug development sectors," Aptamer notes. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
Aptamer Group PLC - York, England-based provider of custom services, diagnostics and therapeutics for biotechnology and pharmaceutical firms - For the year ended June 30, revenue is expected to more than double to GBP4.0 million from GBP1.6 million reported the prior 15-month period. Read More